by Brent Vandermeer | Feb 9, 2021 | Monthly Reviews
Last month seemed to have a different market‐shaping event every other day. While the introduction of a vaccine will help mitigate some future volatility around COVID‐19 infection rates, it’s already obvious 2021 will not…
by Brent Vandermeer | Jan 12, 2021 | Monthly Reviews
The juxtaposition of strong financial markets within a struggling global economy in 2020 highlighted how different the two can act. The S&P 500, typically a bellwether for stocks due to its broad sector diversification and revenue sources, ended the year…
by Brent Vandermeer | Dec 7, 2020 | Monthly Reviews
In a remarkably short time, three pharmaceutical heavyweights (Pfizer, Moderna, and AstraZeneca) have announced they’re nearing the final stages of developing a COVID-19 vaccine. The surprisingly high…
by Brent Vandermeer | Nov 5, 2020 | Monthly Reviews
Throughout October, investors took positions to de-risk portfolios in the run-up to the U.S. Presidential election. This de-risking, coupled with rising COVID infections and new lockdowns in Europe, resulted in…
by Brent Vandermeer | Oct 6, 2020 | Monthly Reviews
As lockdown restrictions eased, a second wave of COVID cases surged across Europe and India. As a result, mobility-tracking data produced by Google and Apple shows people are willingly travelling less in these regions, putting increased pressure on…
by Brent Vandermeer | Sep 10, 2020 | Monthly Reviews
Over the early summer months, global economies have shown improvements. Jobs, retail sales, food services, and industrial production have been experiencing significant bounces. As we head into the fall…